UY33503A - Imidazo [1,2-a]pirimidinas y piridinas sustituidas - Google Patents

Imidazo [1,2-a]pirimidinas y piridinas sustituidas

Info

Publication number
UY33503A
UY33503A UY0001033503A UY33503A UY33503A UY 33503 A UY33503 A UY 33503A UY 0001033503 A UY0001033503 A UY 0001033503A UY 33503 A UY33503 A UY 33503A UY 33503 A UY33503 A UY 33503A
Authority
UY
Uruguay
Prior art keywords
pyridins
pyrimidins
imidazo
replaced
compounds
Prior art date
Application number
UY0001033503A
Other languages
English (en)
Inventor
Dr Stuart Ince
Haegebarth Andrea
Dr Oliver Politz
Dr Ronald Neuhaus
Dr William Scott
Dr Ulf Boemer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY33503A publication Critical patent/UY33503A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Abstract

Compuestos de fórmula (I) que son inhibidores efectivos de la vía Pi3K/Akt, procesos para su producción y su uso como compuestos farmacéuticos.
UY0001033503A 2010-07-12 2011-07-11 Imidazo [1,2-a]pirimidinas y piridinas sustituidas UY33503A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10169205 2010-07-12
US39277910P 2010-10-13 2010-10-13

Publications (1)

Publication Number Publication Date
UY33503A true UY33503A (es) 2012-02-29

Family

ID=44532777

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033503A UY33503A (es) 2010-07-12 2011-07-11 Imidazo [1,2-a]pirimidinas y piridinas sustituidas

Country Status (10)

Country Link
US (1) US8975265B2 (es)
EP (1) EP2593451B1 (es)
JP (1) JP5830094B2 (es)
CN (1) CN103097384B (es)
AR (1) AR090005A1 (es)
CA (1) CA2804845A1 (es)
ES (1) ES2552841T3 (es)
TW (1) TW201206933A (es)
UY (1) UY33503A (es)
WO (1) WO2012007345A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013025732B1 (pt) * 2011-04-06 2022-02-22 Taiho Pharmaceutical Co., Ltd Compostos de imizazo-oxazina, seus usos e composição farmacêutica e fármaco compreendendo os mesmos
ME02316B (me) 2011-04-07 2016-06-20 Bayer Ip Gmbh Imidazopiridazini kao inhibitori akt kinaze
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
EP2802588B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
CA2877550C (en) * 2012-07-13 2020-09-08 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016136928A1 (ja) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
MX2018001706A (es) 2015-08-12 2018-09-06 Incyte Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109734713B (zh) * 2019-03-07 2021-06-04 东华理工大学 一种3-亚胺基咪唑并[1,2-a]吡啶化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1898903E (pt) * 2005-06-10 2013-06-28 Merck Sharp & Dohme Inibidores da atividade de akt
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
ATE503757T1 (de) * 2007-08-14 2011-04-15 Bayer Schering Pharma Ag Kondensierte imidazole zur krebsbehandlung
BRPI0908906A2 (pt) 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
WO2009148916A1 (en) * 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
WO2010088177A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds

Also Published As

Publication number Publication date
JP5830094B2 (ja) 2015-12-09
ES2552841T3 (es) 2015-12-02
CN103097384B (zh) 2017-02-15
CN103097384A (zh) 2013-05-08
WO2012007345A3 (en) 2012-04-12
EP2593451A2 (en) 2013-05-22
US20130190332A1 (en) 2013-07-25
EP2593451B1 (en) 2015-08-19
JP2013531684A (ja) 2013-08-08
WO2012007345A2 (en) 2012-01-19
TW201206933A (en) 2012-02-16
AR090005A1 (es) 2014-10-15
US8975265B2 (en) 2015-03-10
CA2804845A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CR20130213A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogènesis
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015019508A8 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CO6511228A2 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY33616A (es) Compuestos con estructura de imidazotriazinona
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP11011258A (es) Pirimidinas fusionadas
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
GT201400090A (es) 2-tiopirimidinonas
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY34273A (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807